Premium
The effects of black seed supplementation on cardiovascular risk factors in patients with nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled clinical trial
Author(s) -
Darand Mina,
Darabi Zahra,
Yari Zahra,
Hedayati Mehdi,
Shahrbaf Mohammad Amin,
Khoncheh Ahmad,
HosseiniAhangar Behnam,
Alavian Seyed Moayyed,
Hekmatdoost Azita
Publication year - 2019
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.6424
Subject(s) - nonalcoholic fatty liver disease , medicine , placebo , insulin resistance , nigella sativa , steatosis , fatty liver , confounding , quantitative insulin sensitivity check index , gastroenterology , diabetes mellitus , randomized controlled trial , lipid profile , insulin , endocrinology , disease , traditional medicine , cholesterol , insulin sensitivity , pathology , alternative medicine
Nonalcoholic fatty liver disease (NAFLD) is highly related to cardiovascular disorders risk factors. This study aimed to evaluate the effects of black seed ( Nigella sativa ) supplementation on cardiovascular disorders risk factors in patients with NAFLD. This randomized, double‐blind, placebo‐controlled clinical trial was conducted on 50 patients with NAFLD. Participants were assigned to receive a lifestyle modification plus 2 g/day of either N. sativa or placebo for 12 weeks. Compared with the placebo, N. sativa supplementation led to significant reductions in serum glucose (−7.95 vs. −1.22; p = .041), serum insulin (−3.87 vs. −1.07; p = .027), homeostatic model of assessment for insulin resistance (−1.02 vs. −0.28; p = .021), and a significant increase in quantitative insulin sensitivity check index (0.03 vs. 0.006; p = .002). All of these changes were remained significant after adjusting for known confounding variables; however, there was no significant difference in lipid profile changes between the two groups ( p = .05). N. sativa supplementation significantly decreased hepatic steatosis percentage compared with the placebo after adjustment for confounding variables ( p = .005). In conclusion, our results indicate that daily intake of 2‐g N. sativa plus lifestyle modification is superior to lifestyle modification alone in amelioration of insulin resistance and hepatic steatosis in patients with NAFLD.